Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial.
Two lower doses of a once-weekly injection helped people lose roughly 20% of their body weight over 68 weeks, suggesting more flexible treatment options for weight management.
Phase 3b multicentre double-blind RCT (n=309, 24 sites, 5 countries, NCT06388187) demonstrated that once-weekly subcutaneous CagriSema at 1·7 mg and 1·0 mg doses each achieved approximately 20–21% mean bodyweight reduction at 68 weeks versus 2% with pooled placebo, meeting coprimary endpoints with high statistical confidence. Both doses had a similar AE profile (mostly mild/moderate GI events, no deaths), suggesting lower-dose CagriSema options could expand treatment flexibility beyond the 2·4 mg reference dose.
What the study was
- Study design
- Phase 3b multicentre randomised double-blind within-dose-level placebo-controlled parallel-group trial
- Category
- Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
- Maturity
- Potentially Practice-Changing
- Journal
- Lancet Diabetes Endocrinol
Why it surfaced
Phase 3b RCT of a novel amylin-GLP-1 receptor co-agonist combination (cagrilintide + semaglutide) confirms ~20% weight loss at two lower dose levels, expanding the dosing landscape for obesity pharmacotherapy. Published in Lancet Diabetes Endocrinol. Novo Nordisk funded; industry COIs declared.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.